Vor shares new da­ta for stem cell ther­a­py; Melin­ta part­ners with Ve­na­torx on an­tibi­ot­ic un­der FDA re­view

Plus, news about BeiGene, Zymeworks, Rz­nomics, and Adicet:

Vor Bio shares ear­ly da­ta for its gene-edit­ed stem cell ther­a­py: The com­pa­ny an­nounced Thurs­day that its stem cell treat­ment seemed to en­graft nor­mal­ly in sev­en pa­tients with acute myeloid leukemia (AML) treat­ed so far. Three pa­tients who re­ceived My­lotarg — Pfiz­er’s AML drug — saw “pro­tec­tion from deep cy­tope­nias,” or a steep drop in blood cell counts that’s of­ten seen as a side ef­fect of the drug. My­lotarg tar­gets CD33, an anti­gen found in high lev­els on leukemia cells but al­so ex­pressed in some nor­mal cells. Vor, found­ed on re­search led by Sid­dhartha Mukher­jee, ed­its CD33 out of donor stem cells with the goal of spar­ing pa­tients from the treat­ment’s side ef­fects. More da­ta are set to be pre­sent­ed at ASH, the com­pa­ny an­nounced last week. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER